Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. Am J Hematol 2022 Jul;97(7):E232-E235
Date
03/27/2022Pubmed ID
35338673DOI
10.1002/ajh.26546Scopus ID
2-s2.0-85127372897 (requires institutional sign-in at Scopus site) 23 CitationsAuthor List
Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, Stahl M, Liu Y, Dinner S, Palmisiano N, Litzow MR, Foran JMAuthor
Ehab L. Atallah MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Hematopoietic Stem Cell TransplantationHumans
Leukemia, Myeloid, Acute
Tumor Suppressor Protein p53
